Posted by Michael Wonder on 23 Jul 2022
CHMP adopts positive opinion recommending Veklury (remdesivir) receive full marketing authorisation for the treatment of patients with COVID-19
22 July 2022 - If Granted by the European Commission, Veklury will become the only direct-acting antiviral with full marketing authorisation in the European Union.
Gilead Sciences today announced that the CHMP of the European Commission adopted a positive opinion on the fulfillment of the last specific obligation and recommended the granting of marketing authorisation for Veklury (remdesivir) that is no longer subject to specific obligations.
